Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine
Headache: The Journal of Head and Face Pain Nov 13, 2019
Winner PK, Spierings ELH, Yeung PP, et al. - Researchers sought to appraise the onset of efficacy for fremanezumab in chronic migraine by assessing pain-related clinical measures at different time points. In this double-blind phase III study, they randomized 1,130 patients to receive either subcutaneous injections of fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), fremanezumab monthly (675 mg at baseline, 225 mg at weeks 4 and 8), or placebo at each time point (fremanezumab quarterly, n = 376; fremanezumab monthly, n = 379; or placebo, n = 375). Compared with the placebo group, all fremanezumab group exhibited a reduction in the mean number of monthly headache days of at least moderate severity during the 4-week period after the first dose. The analysis suggests the potential of the early onset of efficacy of fremanezumab for improving patient compliance and clinical outcomes.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries